Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
Brian G. Feagan(Western University), Asit Parikh, Stephen B. Hanauer(Northwestern University), Jean‐Frédéric Colombel(Mount Sinai Hospital), Bruce E. Sands(Icahn School of Medicine at Mount Sinai), William J. Sandborn(University of San Diego), Gert Van Assche(KU Leuven), Silvio Danese(IRCCS Ospedale San Raffaele), Hyo Jong Kim(Soongsil University), Serap Sankoh(Millennium Engineering and Integration (United States)), Jing Xu(Kunming Medical University), Paul Rutgeerts(KU Leuven), Tim Wyant(Curis (United States)), Catherine Milch(Millennium Engineering and Integration (United States)), Jeffrey Axler, Irving H. Fox(Takeda (United States))
Cited by 2,891
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment
|Genome biology|2012|2.8k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k